RSV 276
/ National Institute of Allergy and Infectious Diseases
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
February 21, 2025
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
(clinicaltrials.gov)
- P1/2 | N=67 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Completed ➔ Terminated; The study closed to enrollment prior to fully accruing due to difficulties with slower than expected accrual.
Trial termination • Respiratory Diseases • Respiratory Syncytial Virus Infections
May 20, 2024
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
(clinicaltrials.gov)
- P1/2 | N=67 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting ➔ Completed
Trial completion • Respiratory Diseases • Respiratory Syncytial Virus Infections
January 29, 2024
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
(clinicaltrials.gov)
- P1/2 | N=67 | Active, not recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Active, not recruiting | N=130 ➔ 67
Enrollment change • Enrollment closed • Respiratory Diseases • Respiratory Syncytial Virus Infections
December 16, 2022
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
(clinicaltrials.gov)
- P1/2 | N=160 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial completion date • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 4
Of
4
Go to page
1